BACKGROUND: HtrA1, a serine protease, is down-regulated in various human solid tumors. Overexpression of HtrA1 in human cancer cells inhibits cell growth and proliferation in vitro and in vivo, suggesting its possible...BACKGROUND: HtrA1, a serine protease, is down-regulated in various human solid tumors. Overexpression of HtrA1 in human cancer cells inhibits cell growth and proliferation in vitro and in vivo, suggesting its possible role as a tumor suppressor. METHODS: Immunohistochemistry was used to determine the expression of HtrA1 in 50 hepatocellular carcinoma specimens and adjacent liver tissues. The correlation between the expression of HtrA1 and the clinico-pathologic data were analyzed. RESULTS: The levels of HtrA1 were lower in tumor tissues than in their adjacent liver tissues. Moreover, an inverse relationship was found between HtrA1 expression and the differentiation of hepatocellular carcinoma. Loss of HtrA1 was more frequently found in tumors in Edmondson grade especially in those with venous invasion, compared to tumors in Edmondson grade I-II. Most importantly, patients with higher HtrA1 expression had a better survival rate. CONCLUSION: All these data suggest an important role of HtrA1 in hepatocellular carcinoma development and progression, which may be a new target for its treatment.展开更多
Objective To investigate the association between genetic polymorphisms of proximal promoter region of apolipoprotein M(apoM)gene and susceptibility of coronary artery diseases(CAD)in Han Chinese population.Methods Two...Objective To investigate the association between genetic polymorphisms of proximal promoter region of apolipoprotein M(apoM)gene and susceptibility of coronary artery diseases(CAD)in Han Chinese population.Methods Two pairs of primers were designed according to the sequence(GenBank accession nos.EU030444.1)and the PCR products of apoM proximal promoter展开更多
Objective To examine whether palmitic acid downregulates ApoM expression and further to investigate its mechanism.Methods Human hepatoma cell line,HepG2 cells were treated with the media containing palmitic acid(1 mmo...Objective To examine whether palmitic acid downregulates ApoM expression and further to investigate its mechanism.Methods Human hepatoma cell line,HepG2 cells were treated with the media containing palmitic acid(1 mmol/L)and/or PI-3K inhibitor LY294002(10μmol/L),protein kinase C inhibitor GF109203X(GFX,2μmol/L)and/or PARβ/δantagonist展开更多
文摘BACKGROUND: HtrA1, a serine protease, is down-regulated in various human solid tumors. Overexpression of HtrA1 in human cancer cells inhibits cell growth and proliferation in vitro and in vivo, suggesting its possible role as a tumor suppressor. METHODS: Immunohistochemistry was used to determine the expression of HtrA1 in 50 hepatocellular carcinoma specimens and adjacent liver tissues. The correlation between the expression of HtrA1 and the clinico-pathologic data were analyzed. RESULTS: The levels of HtrA1 were lower in tumor tissues than in their adjacent liver tissues. Moreover, an inverse relationship was found between HtrA1 expression and the differentiation of hepatocellular carcinoma. Loss of HtrA1 was more frequently found in tumors in Edmondson grade especially in those with venous invasion, compared to tumors in Edmondson grade I-II. Most importantly, patients with higher HtrA1 expression had a better survival rate. CONCLUSION: All these data suggest an important role of HtrA1 in hepatocellular carcinoma development and progression, which may be a new target for its treatment.
文摘Objective To investigate the association between genetic polymorphisms of proximal promoter region of apolipoprotein M(apoM)gene and susceptibility of coronary artery diseases(CAD)in Han Chinese population.Methods Two pairs of primers were designed according to the sequence(GenBank accession nos.EU030444.1)and the PCR products of apoM proximal promoter
文摘Objective To examine whether palmitic acid downregulates ApoM expression and further to investigate its mechanism.Methods Human hepatoma cell line,HepG2 cells were treated with the media containing palmitic acid(1 mmol/L)and/or PI-3K inhibitor LY294002(10μmol/L),protein kinase C inhibitor GF109203X(GFX,2μmol/L)and/or PARβ/δantagonist
